VANCOUVER, BC, June 7, 2022
/CNW/ - NeutriSci International Inc. ("NeutriSci" or the
"Company") (TSXV: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9), an innovative technology
company developing products, licencing, IP and technology for B2B
partnerships and the nutraceutical industry, is pleased to announce
that it has shipped an additional order to Tabletz LLC.
Tabletz LLC has been shipped the second half of its approximate
$250,000 USD purchase order, which is
destined to one of its distribution partners in Japan. The Tabletz brand products, in Mint,
Lemon and Berry flavours, were shipped by air and expected to
arrive in Japan in the coming
days. This second half of their initial order will make its way to
its distribution partner and then be distributed to retail shelves
in the coming weeks.
Glen Rehman, CEO of NeutriSci,
commented, "This order was requested by Tabletz to be broken up
into two equal halves with the second half being shipped last week.
The order is for a new partner of Tabletz LLC, and they and their
distribution partners continue to expand the distribution network
in Japan. Previous purchase orders
are still in effect. We look forward to continuing to build out the
network with Tabletz LLC."
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production, and
formulation of nutraceutical products. Established in 2009,
NeutriSci's is building sustainable sales models with Convenience,
Chain Drug, and Mass Market and Supermarket retailers for its
products offering co-branding as well as private label
opportunities and contract manufacturing services. For more
information, please visit: www.neutrisci.com.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
Tel: (403) 264-6320
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accept responsibility for the adequacy or accuracy of
this release.
This news release may include forward-looking statements that
are subject to risks and uncertainties. All statements within,
other than statements of historical fact, are to be considered
forward-looking. Although the Company believes the
expectations expressed in such forward-looking statements are based
on reasonable assumptions, such statements are not guarantees of
future performance and actual results or developments may differ
materially from those in forward-looking statements. Factors
that could cause actual results to differ materially from those in
forward-looking statements include market prices, continued
availability of capital and financing, and general economic, market
or business conditions. There can be no assurances that such
statements will prove accurate and, therefore, readers are advised
to rely on their own evaluation of such uncertainties. We do
not assume any obligation to update any forward-looking statements
except as required under the applicable laws.
Statements in this press release have not been evaluated by
the Food and Drug Administration. Products or ingredients are
not intended to diagnose, treat, cure, or prevent any
disease.
SOURCE NeutriSci International Inc.